Printer Friendly

BIOPLASTY, INC. ANNOUNCES SECOND QUARTER 1993 RESULTS OF OPERATIONS

 ST. PAUL, Minn., March 18 /PRNewswire/ -- Bioplasty, Inc. (NASDAQ-NMS: BIOP) net revenue for the three and six months ended Jan. 31, 1993, was $974,458 and $1,895,161, respectively, compared to net revenues of $1,779,862 and $4,377,288, respectively, for the three and six months ended Jan. 31, 1992. Decreased revenue in fiscal 1993 is the result of the cessation of sales of MISTI and MISTI GOLD breast implants in the United States and overseas by the end of April 1992. Net revenue for the quarter ended Oct. 31, 1992, was $920,073. The $53,755 increase in net revenue from the first to the second quarter of fiscal 1993 was primarily the result of increasing sales of Macroplastique Implants overseas.
 Operating expenses (excluding litigation costs and legal fees) for the three and six months ended Jan. 31, 1993, totaled $1,311,546 and $2,930,347, respectively, as compared to operating expenses of $2,215,086 and $4,316,911, respectively, in the three and six months ended Jan. 31, 1992. The significant reductions in operating expenses are the result of cost reductions made by management in reaction to the company's inability to market numerous products, such as MISTI and MISTI GOLD breast implants and certain burn care dressings, pursuant to FDA regulatory circumstances during fiscal 1992 and 1993. Litigation costs and legal fees for the three months ended Jan. 31, 1992, includes a charge of $3.3 million for the then estimated settlement cost of the class action shareholder suit, and in the three months ended Jan. 31, 1993, a credit of $1.925 million for a reduction in the shareholder suit accrual pursuant to its renegotiation and ultimate settlement in February 1993.
 Bioplasty, Inc. business is the development, manufacturing and marketing of certain plastic surgery and urology products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol BIOP.
 BIOPLASTY, INC.
 SUMMARY OF OPERATIONS
 Three Months Ended Six Months Ended
 1/31/93 1/31/92 1/31/93 1/31/92
 Net revenue $974,458 $1,778,862 $1,895,161 $4,377,288
 Gross profit 625,366 704,812 1,119,632 2,349,026
 Operating gain (loss) 836,095 (4,916,266) (565,276) (5,744,846)
 Income tax
 expense (benefit) 2,276 (403,215) (4,375) (569,000)
 Net loss $(683,497)$(4,368,963)$(2,264,839)$(4,838,365)
 Loss per share $(.15) $(1.09) $(.50) $(1.21)
 -0- 3/18/93
 /CONTACT: Daniel G. Holman, president and CEO; or Donald A. Major, V.P. of finance, both of Bioplasty, 612-378-1180/
 (BIOP)


CO: Bioplasty, Inc. ST: Minnesota IN: MTC SU: ERN

KH -- MN011 -- 7626 03/18/93 16:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1993
Words:457
Previous Article:UNIVERSAL INTERNATIONAL ANNOUNCES MANAGEMENT CHANGES
Next Article:SUNRISE LEASING CORPORATION FILES REGISTRATION STATEMENT WITH SECURITIES AND EXCHANGE COMMISSION
Topics:


Related Articles
BIOPLASTY, INC. ANNOUNCES FISCAL 1992 OPERATING RESULTS
BIOPLASTY ANNOUNCES FIRST QUARTER OPERATING RESULTS
BIOPLASTY ANNOUNCES SECOND QUARTER RESULTS OF OPERATIONS
BIOPLASTY ANNOUNCES THIRD QUARTER RESULTS OF OPERATIONS
BIOPLASTY, INC. ANNOUNCES PROHIBITION OF SPIN OFF RECOMMENDED
BIOPLASTY, INC. ANNOUNCES RESIGNATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER
BIOPLASTY, INC. REACHES TENTATIVE AGREEMENT TO SETTLE SHAREHOLDERS' SUIT
OWENS & MINOR, INC., ANNOUNCES IMPROVED 1993 SECOND QUARTER AND SIX-MONTH EARNINGS
BIOPLASTY, INC. FILES PLAN OF REORGANIZATION
BIOPLASTY ANNOUNCES EXTENSION OF RECORD DATE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters